Transcriptomics

Dataset Information

0

The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression


ABSTRACT: The transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20-30% of primary human breast cancers and that correlates with poor prognosis. We show Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased self-renewal capacity, mesenchymal marker expression, motility and metastasis, and represses an adult tissue stem cell gene signature downregulated in cancers. By in silico screening, we identified candidate therapeutics that at low concentrations inhibit growth of cancer cells expressing high ZNF217. We demonstrate that the nucleoside analog triciribine inhibits ZNF217-induced tumor growth and chemotherapy resistance, and inhibits signaling events (e.g., P-AKT, P-MAPK) in vivo. Our data suggest ZNF217 is a biomarker of poor prognosis and a therapeutic target in breast cancer patients, and triciribine may be part of a personalized treatment strategy in patients overexpressing ZNF217. Since ZNF217 is amplified in numerous cancers, these results have implications for other cancers.

ORGANISM(S): Mus musculus

PROVIDER: GSE24727 | GEO | 2012/05/18

SECONDARY ACCESSION(S): PRJNA132345

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2012-05-17 | E-GEOD-24727 | biostudies-arrayexpress
2015-05-18 | GSE38047 | GEO
2015-05-18 | E-GEOD-38047 | biostudies-arrayexpress
2014-06-15 | E-GEOD-58326 | biostudies-arrayexpress
2014-06-15 | GSE58326 | GEO
2007-01-25 | GSE6624 | GEO
2010-06-12 | E-GEOD-6625 | biostudies-arrayexpress
2007-01-25 | GSE6625 | GEO
2007-01-25 | GSE6627 | GEO
2012-02-06 | GSE35511 | GEO